<DOC>
	<DOCNO>NCT00427011</DOCNO>
	<brief_summary>Phase IIb open-label extension study patient Parkinson 's Disease . All patient receive active study drug . The study involve outpatient visit . Patients complete Study E2007-A001-214 ( Cohorts I II ) meet inclusion/exclusion criterion enrol enter 12-week Titration Phase ( `` Dispense Study Drug '' Week 0 [ Visit 2 ] Week 12 [ Visit 7 ] ) follow Maintenance Phase ( Week 12 [ Visit 7 ] end study ) .</brief_summary>
	<brief_title>A Study E2007 In Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Male female patient idiopathic Parkinson 's disease fulfil entry criterion E2007A001214 complete study include end treatment ( Day 70 ) visit Followup Visit Day 91 . EXCLUSION CRITERIA 1 . Pregnant lactating woman . 2 . Women child bear potential unless infertile ( include surgically sterile ) practice effective contraception ( e.g. , intrauterine device barrier method plus hormonal method ) . These patient must negative serum beta human chorionic gonadotropin ( BHCG ) test initial visit ( Visit 1 ) urine pregnancy test throughout study . These patient must also willing remain current form contraception duration study . Postmenopausal woman may recruit must amenorrhoeic least 1 year consider nonchildbearing potential determine investigator . 3 . Patients withdraw Study 214 prior final efficacy visit reason , include lack efficacy . 4 . Patients serious adverse event Study 214 either ongoing possibly probably related study drug . 5 . Patients ongoing adverse event Study 214 think relate E2007 . 6 . Patients past ( within past 5 year ) present history drug alcohol abuse per criterion Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM IV ) . 7 . Patients past ( within 1 year ) present history psychotic symptom require antipsychotic treatment . 8 . Patients past ( within 1 year ) present history suicidal ideation suicide attempt . 9 . Patients active hepatic disease , significantly reduce hepatic function significantly elevate liver enzyme ( abnormal bilirubin serum transaminase level 1.5 time upper limit normal range ) . 10 . Patients clinically significant ECG abnormality , include prolonged QTc ( define QTc &gt; = 450 msec use Fridericia 's correction ) . 11 . Patients clinically significant cardiovascular , metabolic , respiratory , renal , endocrinological , gastrointestinal disease , psychiatric disorder , bacterial viral infection within previous 30 day . 12 . Patients currently take medication know induce enzyme cytochrome P450 3A4 . 13 . Patients current prior treatment ( within 4 week entry visit ) tolcapone , methyldopa , budipine , reserpine , seroquel , intermittent use either liquid form levodopa subcutaneous apomorphine . 14 . Patients previous stereotactic surgery ( e.g. , pallidotomy ) Parkinson 's disease plan stereotactic surgery study period . 15 . Patients receive plan ( next 6 month ) deep brain stimulation . 16 . Patients condition affect peripheral central sensory system , unless relate Parkinson 's disease ( mild sensory pain syndrome limit OFF period ) , could interfere evaluation symptom cause study drug . 17 . Patients condition would make patient , opinion investigator , unsuitable study . 18 . Patients receive investigational product ( E2007 ) within 4 week screen . 19 . Patients clinically significant cognitive impairment ( minimental state examination [ MMSE ] &lt; 24 fulfil DSM IV criterion dementia due Parkinson 's disease ) . 20 . Patients condition could , opinion investigator , place patient increase risk likely prevent completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>